Additionally, miR-1228 via the downregulation of the macrophage migration inhibitory factor (MIF) serves as a negative regulator of gastric-cancer growth and angiogenesis, supporting its use as a potential therapeutic target for anti-angiogenic therapy against gastric cancer [103]. The gene discussed is MIF; the disease is gastric cancer.